Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis

Onno W Akkerman; Floris Grasmeijer; Wiel C M de Lange; Huib A M Kerstjens; Gerard de Vries; Mathieu S Bolhuis; Jan-Willem Alffenaar; Henderik W Frijlink; Grace Smith; Roger Gajraj; Rina de Zwaan; Paul Hagedoorn; Martin Dedicoat; Dick van Soolingen; Tjip S van der Werf

doi:10.1183/13993003.02490-2017

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis

Onno W Akkerman
, Floris Grasmeijer
, Wiel C M de Lange
, Huib A M Kerstjens
, Gerard de Vries
, Mathieu S Bolhuis
, Jan-Willem Alffenaar
, Henderik W Frijlink
, Grace Smith
, Roger Gajraj
, Rina de Zwaan
, Paul Hagedoorn
, Martin Dedicoat
, Dick van Soolingen
, Tjip S van der Werf

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

9 Citations (Scopus)

402 Downloads (Pure)

Abstract

Extensively drug-resistant tuberculosis (XDR-TB) is defined by resistance to isoniazid, rifampicin, any fluoroquinolone and at least one of the three second line injectable drugs, such as amikacin. Drugs toxicity and duration impair adherence to treatment and outcome is rather poor [1]. We report on a particularly challenging XDR-TB patient with persistent non-adherence to treatment and an exceptionally complex drug susceptibility pattern.

Original language	English
Article number	1702490
Number of pages	4
Journal	European Respiratory Journal
Volume	51
Issue number	3
DOIs	https://doi.org/10.1183/13993003.02490-2017
Publication status	Published - 22-Mar-2018

Keywords

MYCOBACTERIUM-TUBERCULOSIS
COLISTIN

Access to Document

10.1183/13993003.02490-2017Licence: CC BY-NC

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosisFinal publisher's version, 358 KBLicence: CC BY-NC

Handle.net

Persistent link

Cite this

Akkerman, O. W., Grasmeijer, F., de Lange, W. C. M., Kerstjens, H. A. M., de Vries, G., Bolhuis, M. S., Alffenaar, J.-W., Frijlink, H. W., Smith, G., Gajraj, R., de Zwaan, R., Hagedoorn, P., Dedicoat, M., van Soolingen, D., & van der Werf, T. S. (2018). Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. European Respiratory Journal, 51(3), Article 1702490. https://doi.org/10.1183/13993003.02490-2017

@article{5d04bb34311b4d89beffaa49eef2b240,

title = "Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis",

abstract = "Extensively drug-resistant tuberculosis (XDR-TB) is defined by resistance to isoniazid, rifampicin, any fluoroquinolone and at least one of the three second line injectable drugs, such as amikacin. Drugs toxicity and duration impair adherence to treatment and outcome is rather poor [1]. We report on a particularly challenging XDR-TB patient with persistent non-adherence to treatment and an exceptionally complex drug susceptibility pattern.",

keywords = "MYCOBACTERIUM-TUBERCULOSIS, COLISTIN",

author = "Akkerman, \{Onno W\} and Floris Grasmeijer and \{de Lange\}, \{Wiel C M\} and Kerstjens, \{Huib A M\} and \{de Vries\}, Gerard and Bolhuis, \{Mathieu S\} and Jan-Willem Alffenaar and Frijlink, \{Henderik W\} and Grace Smith and Roger Gajraj and \{de Zwaan\}, Rina and Paul Hagedoorn and Martin Dedicoat and \{van Soolingen\}, Dick and \{van der Werf\}, \{Tjip S\}",

year = "2018",

month = mar,

day = "22",

doi = "10.1183/13993003.02490-2017",

language = "English",

volume = "51",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "EUROPEAN RESPIRATORY SOC JOURNALS LTD",

number = "3",

}

Akkerman, OW , Grasmeijer, F , de Lange, WCM , Kerstjens, HAM, de Vries, G, Bolhuis, MS , Alffenaar, J-W , Frijlink, HW, Smith, G, Gajraj, R, de Zwaan, R, Hagedoorn, P, Dedicoat, M, van Soolingen, D & van der Werf, TS 2018, 'Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis', European Respiratory Journal, vol. 51, no. 3, 1702490. https://doi.org/10.1183/13993003.02490-2017

TY - JOUR

T1 - Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis

AU - Akkerman, Onno W

AU - Grasmeijer, Floris

AU - de Lange, Wiel C M

AU - Kerstjens, Huib A M

AU - de Vries, Gerard

AU - Bolhuis, Mathieu S

AU - Alffenaar, Jan-Willem

AU - Frijlink, Henderik W

AU - Smith, Grace

AU - Gajraj, Roger

AU - de Zwaan, Rina

AU - Hagedoorn, Paul

AU - Dedicoat, Martin

AU - van Soolingen, Dick

AU - van der Werf, Tjip S

PY - 2018/3/22

Y1 - 2018/3/22

N2 - Extensively drug-resistant tuberculosis (XDR-TB) is defined by resistance to isoniazid, rifampicin, any fluoroquinolone and at least one of the three second line injectable drugs, such as amikacin. Drugs toxicity and duration impair adherence to treatment and outcome is rather poor [1]. We report on a particularly challenging XDR-TB patient with persistent non-adherence to treatment and an exceptionally complex drug susceptibility pattern.

AB - Extensively drug-resistant tuberculosis (XDR-TB) is defined by resistance to isoniazid, rifampicin, any fluoroquinolone and at least one of the three second line injectable drugs, such as amikacin. Drugs toxicity and duration impair adherence to treatment and outcome is rather poor [1]. We report on a particularly challenging XDR-TB patient with persistent non-adherence to treatment and an exceptionally complex drug susceptibility pattern.

KW - MYCOBACTERIUM-TUBERCULOSIS

KW - COLISTIN

U2 - 10.1183/13993003.02490-2017

DO - 10.1183/13993003.02490-2017

M3 - Comment/Letter to the editor

C2 - 29419442

SN - 0903-1936

VL - 51

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 3

M1 - 1702490

ER -

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this